Elspeth Morrison Beauchamp

  • 992 Citations
20082019

Research output per year

If you made any changes in Pure these will be visible here soon.

Personal profile

Research Interests

Dr. Beauchamp's research has focused on developing drugs for non-traditional targets through inhibiting protein-protein interactions in order to affect cellular function and target cancer cells. Current work is investigating novel interactors with mTORC components in order to developing novel therapeutic strategies that target the mTOR pathways in myeloid leukemias.

Education/Academic qualification

PhD, Georgetown University

… → 2010

Research interests

  • Biochemistry: Proteins
  • Blood Cancer (leukemia and lymphomas)
  • Cancer Biology
  • Drug Discovery
  • Signal Transduction

Fingerprint Dive into the research topics where Elspeth Morrison Beauchamp is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 7 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Grants

  • Research Output

    • 992 Citations
    • 23 Article
    • 2 Comment/debate
    • 1 Review article

    Discovery of novel Mnk inhibitors using mutation-based induced-fit virtual high-throughput screening

    Mishra, R. K., Clutter, M. R., Blyth, G. T., Kosciuczuk, E. M., Blackburn, A. Z., Beauchamp, E. M., Schiltz, G. E. & Platanias, L. C., Oct 1 2019, In : Chemical Biology and Drug Design. 94, 4, p. 1813-1823 11 p.

    Research output: Contribution to journalArticle

  • 1 Scopus citations

    Identification and targeting of novel CDK9 complexes in acute myeloid leukemia

    Beauchamp, E. M., Abedin, S. M., Radecki, S. G., Fischietti, M., Arslan, A. DI., Blyth, G. T., Yang, A., Lantz, C., Nelson, A., Goo, Y. A., Akpan, I., Eklund, E. A., Frankfurt, O., Fish, E. N., Thomas, P. M., Altman, J. K. & Platanias, L. C., Jan 1 2019, In : Blood. 133, 11, p. 1171-1185 15 p.

    Research output: Contribution to journalArticle

  • 6 Scopus citations

    Inhibitory effects of SEL201 in acute myeloid leukemia

    Kosciuczuk, E. M., Kar, A. K., Blyth, G. T., Fischietti, M., Abedin, S., Mina, A. A., Siliezar, R., Rzymski, T., Brzozka, K., Eklund, E. A., Beauchamp, E. M., Eckerdt, F., Saleiro, D. & Platanias, L. C., Jan 1 2019, In : Oncotarget. 10, 67, p. 7112-7121 10 p.

    Research output: Contribution to journalArticle

  • 2 Scopus citations

    Pharmacological mTOR targeting enhances the antineoplastic effects of selective PI3Kα inhibition in medulloblastoma

    Eckerdt, F., Clymer, J., Bell, J. B., Beauchamp, E. M., Blyth, G. T., Goldman, S. & Platanias, L. C., Dec 1 2019, In : Scientific reports. 9, 1, 12822.

    Research output: Contribution to journalArticle

    Open Access
  • 1 Scopus citations

    Potent antineoplastic effects of combined PI3Kα-MNK inhibition in medulloblastoma

    Eckerdt, F., Bell, J. B., Beauchamp, E. M., Clymer, J., Blyth, G. T., Kosciuczuk, E. M., Ma, Q., Chen, D. Z., Horbinski, C., Goldman, S., Munshi, H. G., Hashizume, R. & Platanias, L. C., Jun 1 2019, In : Molecular Cancer Research. 17, 6, p. 1305-1315 11 p.

    Research output: Contribution to journalArticle

  • 3 Scopus citations